Literature DB >> 9511046

Unusual tazobactam-sensitive AmpC beta-lactamase from two Escherichia coli isolates.

G S Babini1, F Danel, S D Munro, P A Micklesen, D M Livermore.   

Abstract

Two Escherichia coli isolates were studied. MIC patterns and hydrolysis assays suggested that they hyperproduced AmpC beta-lactamase, but synergy between ceftazidime and tazobactam was greater than between ceftazidime and Ro 48-1256, whereas the converse pattern is typical of AmpC hyperproducers. Studies with purified beta-lactamase from one of the isolates confirmed that tazobactam was a 100-fold stronger inhibitor than for the classical E. coli AmpC enzyme. Moreover, in contrast to typical AmpC types, the new enzyme had greater affinity for cephaloridine than for benzylpenicillin.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9511046     DOI： 10.1093/jac/41.1.115

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  6 in total

Review 1.  Plasmid-determined AmpC-type beta-lactamases.

Authors:  Alain Philippon; Guillaume Arlet; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 2.  Updated functional classification of beta-lactamases.

Authors:  Karen Bush; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

3.  New method for laboratory detection of AmpC beta-lactamases in Escherichia coli and Klebsiella pneumoniae.

Authors:  K Nasim; S Elsayed; J D D Pitout; J Conly; D L Church; D B Gregson
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

Review 4.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

5.  Inhibitor-sensitive AmpC beta-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins.

Authors:  Yohei Doi; Jun-ichi Wachino; Masaji Ishiguro; Hiroshi Kurokawa; Kunikazu Yamane; Naohiro Shibata; Keigo Shibayama; Keiko Yokoyama; Haru Kato; Tetsuya Yagi; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

6.  Synthesis and enzyme-based evaluation of analogues L-tyrosine thiol carboxylic acid inhibitor of metallo-β-lactamase IMP-1.

Authors:  Omid Khalili Arjomandi; Mahboubeh Kavoosi; Hadi Adibi
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.